Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02059278 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Nephron Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 335
- Enrollment target
NCT02059278 is a Phase 3 study that has completed, run by Nephron Pharmaceuticals Corporation. The registered enrollment target is 335 participants.
The verdict
NCT02059278, a Phase 3 study, has completed, sponsored by Nephron Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 335 participants
- Enrollment target
Study Summary
This is a Phase 3 study to evaluate the safety and efficacy of T-2345 dosed to one of both eyes once daily for 84 days compared to Xalatan dosed to one of both eyes once daily for 84 days in patients with elevated eye pressure.
Interventions
- DRUG Xalatan
- DRUG T-2345
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02059278
The ClinicalTrials.gov registry entry for NCT02059278 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 335 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nephron Pharmaceuticals Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Xalatan is the first listed.
NCT02059278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02059278 about?
NCT02059278 is a clinical study titled "Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension". This is a Phase 3 study to evaluate the safety and efficacy of T-2345 dosed to one of both eyes once daily for 84 days compared to Xalatan dosed to one of both eyes once daily for 84 days in patients with elevated eye pressure.
What is the current status of trial NCT02059278?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 335 participants. The study started on 2014-01. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02059278?
The interventions under investigation include: Xalatan (DRUG), T-2345 (DRUG).
Who is sponsoring clinical trial NCT02059278?
This trial is sponsored by Nephron Pharmaceuticals Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.